Burcon NutraScience Corporation
Burcon NutraScience Corporation is a biotechnology research and ingredients company specializing in plant-based protein technologies for the global food and beverage industry. The company develops high-performance protein ingredients derived from sources such as pea, canola, soy, hemp, sunflower, fava bean, and other plant materials, targeting applications in dairy alternatives, meat analogues, nutritional beverages, and lifestyle nutrition products. Its portfolio includes branded ingredients like Peazazz pea protein, Puratein canola protein, and FavaPro fava bean protein, designed to offer enhanced functionality, solubility, taste, and nutritional profiles for formulators. Burcon also provides pilot plant processing and scale-up validation services, enabling partners to move from lab concepts to commercial production using its proprietary extraction and purification processes. Headquartered in Vancouver, Canada, and founded in 1998, Burcon holds an extensive global patent estate covering composition, application, and process technologies for plant-based proteins, positioning it as a specialist supplier to food manufacturers seeking clean-label, sustainable protein ingredients.
$0.92
+$0.03 (+3.37%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-502.33% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 493.8% YoY with margins expanding 1516.4pp.
Negative free cash flow of -C$10M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
C$3M
▲ +493.8% YoY
Net Income (TTM)
-C$15M
▼ -72.5% YoY
Op. Margin
-376.60%
▲ +1516.4pp YoY
ROIC
-33.44%
▼ -2.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-C$10M
▼ -74.0% YoY
Op. Cash Flow (TTM)
-C$9M
▼ -66.2% YoY
Net Debt
C$23M
Cash & Equiv.
C$951K
3Y CAGR: +136.4%
Continue Research
Is Burcon NutraScience (BRCNF) overvalued?
Burcon NutraScience (BRCNF)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Burcon NutraScience scores 30/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Burcon NutraScience a high-quality business?+
Burcon NutraScience scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -376.6% operating margin and a -33.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Burcon NutraScience a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh BRCNF's valuation and scores 30/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Packaged Foods
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.